Oncogene addiction to c-MYC in myeloma cells

doi:10.18632/oncotarget.631

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Oncogene addiction to c-MYC in myeloma cells

25 Aug 2012

Abstract excerpt

Analysis of DNA from primary cancer cells has revealed large numbers of genetical aberrations, raising questions as to which mutations are “drivers” and which are “passengers”. Applying a small molecular inhibitor of MYC-MAX heterodimerization [1] we recently reported that myeloma cells treated with inhibitor rapidly undergo apoptosis [2]. Thus, a large fraction of primary myeloma cells apparently is dependent on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis
Share to TGF-β signaling in diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed

Identifiers

PMID: 22964579
DOI: 10.18632/oncotarget.631

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Oncogene addiction to c-MYC in myeloma cellsPMID 22964579Read ↗

Addiction to c-MYC in multiple myelomaSemantic proximity Read ↗

Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment.Semantic proximity Read ↗

Chromosomal instability and acquired drug resistance in multiple myelomaSemantic proximity Read ↗

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Semantic proximity Read ↗

Molecular and immunological mechanisms of clonal evolution in multiple myelomaSemantic proximity Read ↗

The Tao of myeloma.Semantic proximity Read ↗

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myelomaSemantic proximity Read ↗

Genomic instability in multiple myeloma: mechanisms and therapeutic implicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.